HARROW, INC. 8K

Harrow, Inc. announced strong second quarter 2026 revenue growth, reiterated full-year guidance, reported a net loss and negative Adjusted EBITDA, and detailed product, acquisition (TYRVAYA), launch (BYOOVIZ), coverage, and pipeline updates for its ophthalmic portfolio.

On August 10, 2026, Harrow, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting a 60% sequential and 11% year-over-year increase in quarterly revenue to $70.7 million, continued strong growth across key ophthalmic products VEVYE, IHEEZO, and TRIESENCE, and the successful July 2026 launch of BYOOVIZ, while reiterating full-year 2026 guidance of $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA despite reporting a quarterly net loss of $17.3 million and negative Adjusted EBITDA of $1.2 million; the company also announced expanded formulary coverage for VEVYE effective August 1, 2026, detailed expectations around its pending acquisition of TYRVAYA anticipated to close in the second half of 2026, and provided updates on multiple pipeline and regulatory milestones, including trials and regulatory interactions for G-MELT, IHEEZO (QUELL), TRIESENCE, NATACYN, YOCHIL, IOPIDINE, and VERKAZIA.

Filing Facts

CIK

1360214

Ticker

HROW

Form

8K

Source Type

fda

Accession

0001493152-26-036865

Alert Tier

6